To further evaluate the therapeutic efficacy of scFv autocrine PD-L1 antibody CAR T cells in solid tumors, we applied an experimental scheme as illustrated in Figure 6A. Similarly, the tumor growth curve (Figure 6B), and the weight and size of dissected tumors (Figure 6C,D) of Her2.BBz.PD-L1 CAR T cell treatment group were significantly decreased compared with those of the Her2.BBz CAR T cell treatment group. Here, ERBB2 is linked to neoplasm.